Results 21 to 30 of about 5,464 (192)

Abciximab for thrombolysis during intracranial aneurysm coiling. [PDF]

, 2008
INTRODUCTION: Thrombotic events are a common and severe complication of endovascular aneurysm treatment with significant impact on patients' outcome.
Byrne, JV, Corkill, Rufus A, Gralla, Jan, Rennie, Adam T M, Gralla, J, Corkill, RA, Kuker, Wilhem, Rennie, AT, Molyneux, Andrew, Byrne, James V, Kuker, Wilhelm, Molyneux, A, Byrne, James, Lalloo, ST, Lalloo, Shivendra T, Kuker, W   +15 more
core   +1 more source

Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration

Trials, 2009
Background Administration of abciximab during primary percutaneous coronary intervention is an effective adjunctive therapy in the treatment of patients with ST-segment elevation myocardial infarction.
Gu Youlan L, Fokkema Marieke L, Kampinga Marthe A, de Smet Bart JGL, Tan Eng S, van den Heuvel Ad FM, Zijlstra Felix   +6 more
doaj   +1 more source

Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials

Journal of Interventional Cardiology, 2022
Objectives. This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Background.
Nan Bai, Ying Niu, Ying Ma, Yao-Sheng Shang, Peng-Yu Zhong, Zhi-Lu Wang   +5 more
doaj   +1 more source

A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results [PDF]

, 2003
Pharmacy and therapeutics committees commonly cite a lack of generalizability as a reason for not incorporating cost-effectiveness information into decision making.
Reed, S.D., Sullivan, S.D., Dillingham, P.W., Briggs, A.H., Veestra, D.L.   +4 more
core   +1 more source

Antiphospholipid syndrome and acute myocardial infarction: Treatment with thrombectomy and abciximab

Revista Portuguesa de Cardiologia, 2014
Antiphospholipid syndrome (APS) is an autoimmune coagulation disorder that manifests clinically as venous and arterial thrombosis, and may affect any tissue or organ. Coronary artery involvement, however, is very rare.
Vicens Martí, Filipe Seixo, Miguel Santaló, Antonio Serra   +3 more
doaj   +1 more source

Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention

Platelets, 2022
Platelet glycoprotein IIb/IIIa inhibitors (GPIs) have been part of the adjuvant treatment of acute coronary syndrome for years. However, real-life data regarding the efficacy and safety of GPIs under the current indications are lacking in the setting of ...
Pablo Revilla-Martí, Jose A. Linares-Vicente, Ana Martínez Labuena, Octavio Jiménez Melo, Paula Morlanes Gracia, Daniel Meseguer González, Antonela Lukic, Borja Simó Sánchez, Jose R. Ruiz Arroyo   +8 more
doaj   +1 more source

FLOW DIVERTER DEVICE IN THE ACUTE SETTING OF RUPTURED BLISTER LIKE ANEURYSM: A CASE REPORT [PDF]

Euromediterranean Biomedical Journal, 2021
Blister-like aneurysms (BLA) are a rare half-dome-shaped aneurysm, with a broad-based appearance, originating more often from a non-branching site of the supraclinoid internal carotid artery (ICA).
Cesare Gaglaiardo
doaj   +1 more source

Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

BMC Cardiovascular Disorders, 2017
Background Thrombolysis is still used when primary angioplasty is delayed for a long time, but 25%–30% of patients require rescue angioplasty (RA). There are no established recommendations for antithrombotic management in RA.
José M. De la Torre Hernández, Mario Sadaba Sagredo, Miren Telleria Arrieta, Federico Gimeno de Carlos, Elena Sanchez Lacuesta, Juan A. Bullones Ramírez, Javier Pineda Rocamora, Victoria Martin Yuste, Tamara Garcia Camarero, Mariano Larman, Jose R. Rumoroso   +10 more
doaj   +1 more source

Abciximab in Acute Ischemic Stroke

, 2000
Background and Purpose —Abciximab is a potent parenterally administered platelet glycoprotein IIb/IIIa antagonist. Because this agent has been shown to improve outcomes in coronary artery disease, there is interest to evaluate ...
The Abciximab in Ischemic Stroke Investigators
core   +1 more source

The use of combination of fibrinolytic therapy and abciximab in the treatment of the acute myocardial infarction with ST elevation [PDF]

Vojnosanitetski Pregled, 2002
Background. According to current knowledge, the best way to treat the acute myocardial infarction with ST elevation is primary transluminal coronary angioplasty, which can be performed only in the best equipped tertiary cardiology centers.
Gligić Branko, Dinčić Dragan, Obradović Slobodan, Marković Milić, Orozović Vjekoslav   +4 more
doaj   +1 more source